Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / IL10

IL10

Basics

Aliases:
This biomarker is also known as:
  • interleukin 10,
  • TGIF,
  • IL-10,
  • CSIF,
  • IL10A,
  • cytokine synthesis inhibitory factor,
  • T-cell growth inhibitory factor,
  • Interleukin-10,

Description…

From NCBI Gene: The protein encoded by this gene is a cytokine produced primarily by monocytes and to a lesser extent by lymphocytes. This cytokine has pleiotropic effects in immunoregulation and inflammation. It down-regulates the expression of Th1 cytokines, MHC class II Ags, and costimulatory molecules on macrophages. It also enhances B cell survival, proliferation, and antibody production. This cytokine can block NF-kappa B activity, and is involved in the regulation of the JAK-STAT signaling pathway. Knockout studies in mice suggested the function of this cytokine as an essential immunoregulator in the intestinal tract. Mutations in this gene are associated with an increased susceptibility to HIV-1 infection and rheumatoid arthritis.[provided by RefSeq, May 2011]

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: IL10

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: One
QA State: Curated

Overview

No additional data available.

Performance Comment

Ninety biomarkers were measured using a series of multiplexed immunoassays and results analyzed by the EDRN data management center splitting the cases and controls into training and validation sets, excluding subjects with DCIS or atypical hyperplasia from the training phase. We found little evidence that any of these markers can discriminate women with invasive cancer from those with benign breast conditions.

Ovary

Attributes

Phase: Two
QA State: Curated

Overview

IL10 alone was not a strong predictor of ovarian cancer.

Performance Comment

Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Publications

No associated publications found.

Biomuta

Mutation Statistics

Gene Name: IL10
UniProt Accession #: P22301
Mutated Sites Count: 29
Associated Pubmed ID Count 6
CancerDO Count 16
Affected Protein Function Sites Count: 4

View in BioMuta